SummaryBceA and bceB encode a nucleotide-binding domain (NBD) and membrane-spanning domain (MSD) subunit, respectively, of an ATP-binding cassette (ABC) transporter in Bacillus subtilis . Disruption of these genes resulted in hypersensitivity to bacitracin, a peptide antibiotic that is non-ribosomally synthesized in some strains of Bacillus . Northern hybridization analyses showed that expression of the bceAB operon is induced by bacitracin present in the growth medium. The bceRS genes encoding a twocomponent regulatory system are located immediately upstream of bceAB . Deletion analyses of the bceAB promoter together with DNase I footprinting experiments revealed that a sensor kinase, BceS, responds to extracellular bacitracin either directly or indirectly and transmits a signal to a cognate response regulator, BceR. The regulator binds directly to the upstream region of the bceAB promoter and upregulates the expression of bceAB genes. The bcrC gene product is additionally involved in bacitracin resistance. The expression of bcrC is dependent on the ECF s s s s factors, s s s s M and s s s s X , but not on the BceRS two-component system. In view of these results, possible roles of BceA, BceB and BcrC in bacitracin resistance of B. subtilis 168 are discussed.
Bacitracin is a peptide antibiotic nonribosomally produced by Bacillus licheniformis. The bcrABC genes which confer bacitracin resistance to the bacitracin producer encode ATP binding cassette (ABC) transporter proteins, which are hypothesized to pump out bacitracin from the cells. Bacillus subtilis 168, which has no bacitracin synthesizing operon, has several genes homologous to bcrABC. It was found that the disruption of Bacitracin is a dodecapeptide antibiotic produced by some strains of Bacillus licheniformis and Bacillus subtilis (2, 11). The synthesis is nonribosomally catalyzed by a multienzyme complex composed of three subunits, BacA, BacB, and BacC, whose genes have been cloned and sequenced (6,9,12,18,22). Bacitracin has potent antibiotic activity against gram-positive bacteria (30). The inhibition of peptidoglycan biosynthesis is the best-characterized bactericidal effect of bacitracin (27). It forms a complex mediated by a metal ion (Zn 2ϩ ) with the lipid C 55 -isoprenyl pyrophosphate (IPP) (24, 26), which is a carrier of a peptidoglycan unit or a disaccharide with pentapeptide across the membrane. Bacitracin, by binding to IPP, inhibits the conversion of IPP to C 55 -isoprenyl phosphate, which is catalyzed by a membrane associated pyrophosphatase (25).B. licheniformis, a bacitracin producer, has an ABC transporter system which is hypothesized to pump out bacitracin for self-protection (19). The transporter is composed of two membrane proteins, BcrB and BcrC, and two identical ATP-binding subunits, BcrA. Neumüller et al. recently reported that in B. licheniformis, bcrABC genes are localized about 3 kb downstream of the bacitracin biosynthetic operon bacABC (14). Between the bacABC operon and bcrABC genes, they also identified bacR and bacS genes which encode proteins with high homology to response regulator and sensory kinase of two-component regulatory systems and are involved in the regulation of bcrA expression.The B. subtilis genome project determined the entire DNA sequence of strain 168 and found that there are two operons which encode nonribosomal peptide antibiotic synthetase complexes (13). One is a surfactin synthetase operon (4), and the other is a plipastatin (fengycin) synthetase operon (29, 31). There is no bacitracin synthetase operon in B. subtilis 168. B. subtilis 168 is more sensitive to bacitracin than B. licheniformis, a bacitracin producer. Heterologous expression of bcrABC transporter in B. subtilis results in an increase of bacitracin resistance to a level similar to that observed in a bacitracin producer (5,19,20). A homology search reveals that in B. subtilis 168, there are several homologues of BcrA, -B, and -C of B. licheniformis. In this study we showed that the disruption of the ywoA gene, which encodes the BcrC homologue, resulted in a marked decrease of resistance to bacitracin. We also reported that the transcription of the ywoA gene was dependent on extracytoplasmic function (ECF) factors, M and X . MATERIALS AND METHODSBacterial strains and plasmids. B. subtilis 168...
In members of one of the subfamilies of the bacterial ATP binding cassette (ABC) transporters, the two nucleotide binding domains are fused as a single peptide and the proteins have no membrane-spanning domain partners. Most of the ABC efflux transporters of this subfamily have been characterized in actinomycetes, producing macrolide, lincosamide, and streptogramin antibiotics. Among 40 ABC efflux transporters of Bacillus subtilis, five proteins belong to this subfamily. None of these proteins has been functionally characterized. We examined macrolide, lincosamide, and streptogramin antibiotic resistance in insertional disruptants of the genes that encode these proteins. It was found that only a disruptant of vmlR (formerly named expZ) showed hypersensitivity to virginiamycin M and lincomycin. Expression of the vmlR gene was induced by the addition of these antibiotics in growth medium. Primer extension analysis revealed that transcription of the vmlR gene initiates at an adenosine residue located 225 bp upstream of the initiation codon. From the analysis of the vmlR and lacZ fusion genes, a 52-bp deletion from ؉159 to ؉211 resulted in constitutive expression of the vmlR gene. In this region, a typical -independent transcriptional terminator was found. It was suggested that the majority of transcription ends at this termination signal in the absence of antibiotics, whereas under induced conditions, RNA polymerase reads through the terminator, and transcription continues to the downstream vmlR coding region, resulting in an increase in vmlR expression. No stabilization of vmlR mRNA occurred under the induced conditions.
The expression of ribosome modulation factor (RMF) is induced during stationary phase in Escherichia coli. RMF participates in the dimerization of 70S ribosomes to form the 100S ribosome, which is the translationally inactive form of the ribosome. To elucidate the involvement of the control of mRNA stability in growth-phasespecific rmf expression, we investigated rmf mRNA stability in stationary-phase cells and cells inoculated into fresh medium. The rmf mRNA was found to have an extremely long half-life during stationary phase, whereas destabilization of this mRNA took place after the culture was inoculated into fresh medium. RMF and 100S ribosomes disappeared from cells 1 min after inoculation. In addition to control by ppGpp-dependent transcription, these results indicate that the modulation of rmf mRNA stability is also involved in the regulation of growth-phase-specific rmf expression. Unexpectedly, the postinoculation degradation of rmf mRNA was suppressed by the addition of rifampin, suggesting that de novo RNA synthesis is necessary for degradation. This degradation was also suppressed in both a poly(A) polymerase-deficient and an rne-131 mutant strain. We cloned and sequenced the 3-proximal regions of rmf mRNAs and found that most of these 3 ends terminated at the -independent terminator with the addition of a one-to five-A oligo(A) tail in either stationary-phase or inoculated cells. No difference was observed in the length of the poly(A) tail between stationary-phase and inoculated cells. These results suggest that a certain postinoculation-specific regulatory factor participates in the destabilization of rmf mRNA and is dependent on polyadenylation.Bacteria have evolved various mechanisms by which they alter gene expression to adapt to changes in environmental and intracellular conditions. The mechanisms through which different genes modulate their expression depend on their respective functions. In some cases, several different mechanisms, such as the control of transcription and translation and the modulation of the stability of the mRNA and protein, are used to regulate the expression of a single gene.Expression of the ribosome modulation factor (RMF) is induced during stationary phase in the presence of ppGpp, which is known to be a mediator of stringent control (17,36,37). RMF binds to the 50S ribosomal subunit to mediate the dimerization of 70S ribosomes to form the 100S ribosome, which is a translationally inactive form (37). In a recent study, it was demonstrated that RMF covers the peptidyl transferase center and the entrance of the peptide exit tunnel (42). The dimerization reaction is reversible, as the 100S ribosomes dissociate back into 70S ribosomes within 2 min after cells are transferred into fresh medium (36, 41) and as protein synthesis and cell proliferation resume within 6 min (38).Recently, we found that the rmf mRNA is extremely stable in stationary-phase cells. In light of the RMF function described above, it is reasonable to assume that the modulation of rmf mRNA stability pla...
A third multidrug transporter gene named bmr3 was cloned from Bacillus subtilis. Although Bmr3 shows relatively low homology to Bmr and Blt, the substrate specificities of these three transporters overlap. Northern hybridization analysis showed that expression of the bmr3 gene was dependent on the growth phase.Bacteria possess pumps of low specificity that can extrude structurally unrelated compounds in an energy-dependent manner (12,16,20). Mutations in the genes encoding these pumps increase the susceptibilities of the mutant bacteria to diverse cytotoxic compounds (11,15,21), and overexpression of these pumps from genes on multicopy plasmids confers multidrug resistance to bacteria (1,13,18,19).Recently, experimental evidence has accumulated showing that some bacteria have multiple drug efflux pumps with overlapping substrate specificities. Escherichia coli has AcrAB and EnvCD efflux pump systems (with more than 65% identical amino acids) and similar substrate specificities (11,(14)(15)(16). In the gram-positive bacterium Bacillus subtilis, two highly homologous (51% identity) multidrug transporters, Bmr and Blt, have been reported (1,18). Overexpression of these transporters was shown to result in increased resistance to the same spectrum of substances. It is not yet clear whether these individual pumps have any specific physiological function other than to protect bacteria from various toxins in the environment.In this article, we report a third multidrug transporter gene of B. subtilis. Overexpression of this gene, bmr3, on a multicopy plasmid resulted in resistance to puromycin, tosufloxacin, and norfloxacin which are also substrates of the two other multidrug transporters of B. subtilis. Bmr3 protein shows moderate homology to EmrB, a multidrug transporter of E. coli (13), and to a lesser extent to Bmr and Blt (1,18). The expression pattern of the bmr3 gene was dependent on the growth phase and different from those of bmr and blt genes. Therefore, these three multidrug transporters might have distinct roles under different physiological conditions.Cloning and sequencing of the bmr3 gene. The cmp gene of E. coli, which is located just downstream of the divE gene, encodes a 23.5-kDa hypothetical membrane protein with unknown function (24). While attempting to clone a homolog of this gene, we obtained a clone, pH233, from a genomic library of B. subtilis 168 cloned into pUC18 that gave a distinct hybridization signal under low-stringency conditions. Sequence analysis showed that the 3.3-kb insert of pH233 contained two open reading frames (ORFs) oriented in opposite directions, as shown in Fig. 1A. Although the 0.7-kb HindIII fragment of ORF 1 (ORF-1) displayed 50% identity with the cmp gene at the level of nucleotide sequence, there was no homology at the level of amino acid sequence. A homology search revealed that the predicted 512 amino acid sequence of ORF-1 showed moderate homology to EmrB (25% identity and 57% similarity), one of the multidrug transporters of E. coli (13), and to a putative protein p...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.